Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, tremelimumab, and bevacizumab in unresectable HCC
NCT05844046Phase 2Recruiting
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab, bevacizumab in hepatocellular carcinoma (HCC). Started Apr 2023; status: recruiting.
02
Drugs
durvalumabtremelimumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05844046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844046.